Nappi Francesco, Avtaar Singh Sanjeet Singh, Salsano Antonio, Nassif Aubin, Shingu Yasushige, Wakasa Satoru, Fiore Antonio, Spadaccio Cristiano, El-Dean Zein
Department of Cardiac Surgery, Centre Cardiologique du Nord., 93200 Saint-Denis, France.
Department of Cardiothoracic Surgery, Royal Infirmary of Edinburgh, Edinburgh EH16 4SA, UK.
J Clin Med. 2024 Dec 18;13(24):7742. doi: 10.3390/jcm13247742.
Secondary mitral regurgitation (SMR) is characterized by a pathological process impacting the left ventricle (LV) as opposed to the mitral valve (MV). In the absence of structural alterations to the MV, the expansion of the LV or impairment of the papillary muscles (PMs) may ensue. A number of technical procedures are accessible for the purpose of determining the optimal resolution for MR. Nevertheless, there is a dearth of rigorous data to facilitate a comparative analysis of MV replacement, MV repair (including subvalvular repair), and transcatheter mitral valve interventions (TMV-Is). The objective of this investigation is to evaluate and compare the efficacy and clinical outcomes of transcatheter mitral valve repair (TMV-r) utilizing the edge-to-edge mitral valve repair (TEER) procedure in comparison to conventional surgical mitral valve interventions (S-SMVis) in patients with secondary mitral regurgitation. A consortium of five cardiac surgery institutions from four European states and Japan have joined forces to establish a multicenter observational registry, designated TEERMISO. Patients who underwent technical procedures for SMR between January 2007 and December 2023 will be enrolled consecutively into the TEERMISO registry. The investigation team evaluated the comparative efficacy of replacement and repair techniques, utilizing both the standard surgical methodology and the transcatheter intervention. The primary clinical outcome will be the degree of left ventricular remodeling, as assessed by the left ventricular end-diastolic volume index, at 10 years. The forthcoming research will assess a variety of secondary endpoints, among which all-cause mortality will be the primary endpoint. Subsequent assessments will be made in the following order: functional status, hospitalization, neurocognition, physiological measures (echocardiographic assessment), occurrence of adverse clinical incidents, and reoperation. The multicenter design of the database is anticipated to reduce the potential for bias associated with institutional caseload and surgical experience. All participating centers possess an established mitral valve protocol that facilitates comprehensive follow-up and management of any delayed mitral complications following replacement surgery or surgical repair of the secondary mitral regurgitation. The data collected will provide insights into the impact of diverse surgical approaches on standard mitral valve surgery and TEER. This will facilitate the evaluation of LV remodeling over the course of long-term post-procedural follow-up. ClinicalTrials.gov ID: NCT05090540; IRB ID: 202201143.
继发性二尖瓣反流(SMR)的特征是一种影响左心室(LV)而非二尖瓣(MV)的病理过程。在二尖瓣无结构改变的情况下,可能会出现左心室扩张或乳头肌(PMs)受损。为确定二尖瓣反流的最佳解决方案,有多种技术手段可供选择。然而,缺乏严格的数据来促进对二尖瓣置换术、二尖瓣修复术(包括瓣下修复)和经导管二尖瓣介入治疗(TMV-Is)进行比较分析。本研究的目的是评估和比较采用缘对缘二尖瓣修复术(TEER)的经导管二尖瓣修复术(TMV-r)与继发性二尖瓣反流患者的传统外科二尖瓣干预术(S-SMVis)的疗效和临床结果。来自四个欧洲国家和日本的五个心脏外科机构联合组成了一个联盟,建立了一个多中心观察性登记处,称为TEERMISO。2007年1月至2023年12月期间接受继发性二尖瓣反流技术手术的患者将连续纳入TEERMISO登记处。研究团队利用标准外科方法和经导管干预评估了置换和修复技术的比较疗效。主要临床结局将是10年后通过左心室舒张末期容积指数评估的左心室重构程度。即将开展的研究将评估各种次要终点,其中全因死亡率将是主要终点。后续评估将按以下顺序进行:功能状态、住院情况、神经认知、生理指标(超声心动图评估)、不良临床事件的发生情况以及再次手术。数据库的多中心设计预计将减少与机构病例数量和手术经验相关的偏倚可能性。所有参与中心都有既定的二尖瓣治疗方案,便于对置换手术或继发性二尖瓣反流手术修复后任何延迟的二尖瓣并发症进行全面随访和管理。收集的数据将深入了解不同手术方法对标准二尖瓣手术和TEER的影响。这将有助于评估术后长期随访过程中的左心室重构情况。ClinicalTrials.gov标识符:NCT05090540;机构审查委员会标识符:202201143。